Financial intelligence for Asia's healthcare markets
Remember me:

13/09/2017

Markets in Asia followed Wall Street higher today as fears about North Korea and damage from Hurricane Irma abated. A stronger US dollar saw both the Nikkei and the ASX make steady gains, though there was weakness elsewhere. The Hang Seng and the SGX declined. “Profit taking could be one reason behind this technical pullback. Technically, the Hang Seng Index is facing strong selling pressure at 28,000 points – a psychological resistance level,” explained Margaret Yang Yan at CMC Markets in Singapore. Chinese markets traded more or less flat.
 
Sisram Medical, a Israeli subsidiary of Shanghai Fosun Pharmaceutical, and which manufactures medical aesthetics devices, has priced its HK$977 million (US$125 million) IPO on the Hong Kong Stock Exchange at the low end of guidance. It sold 110 million shares or around 25% of its total share capital at HK$8.88 per share. The first day of trading is 19 September. Joint sponsors are CICC and Jefferies.
 
Hong Kong-headquartered healthcare services company UMP Healthcare has announced that the public float of the company has fallen below the minimum prescribed percentage of 25% of the total issued share capital. “The company undertakes to procure that appropriate steps will be taken to ensure restoration of the minimum prescribed percentage as soon as reasonably practicable in accordance with the listing rules,” it said, though it admitted that it has not yet determined any definitive proposal.
 
In a scandal which has dominated the Indonesian press since the weekend, shares in Indonesian hospital operator Mitra Keluarga have crashed 5.2% this week after a baby girl died when she was denied paediatric care at one of its hospitals. Her parents claim that it is because they had been unable to pay the hospital’s upfront treatment fees. Its shares were last see flat at Rp2,000 (US$0.15).
 
As part of an internal reorganisation, IHH Healthcare, Asia’s largest healthcare company, has merged its Bulgarian subsidiaries, Acibadem City Clinic EAD and Tokushukai-Sofia. IHH said that this was to streamline Acibadem group’s structure and management, and that it would have no material effect on IHH’s earnings, net assets or gearing.
 
HLIB Research remains cool on medical rubber glove manufacturer Hartalega Holdings after a visit to its new manufacturing complex in Sepang. “Whilst we like Hartalega for its leadership position in the nitrile glove market; high ROE and net profit margins amidst a favourable operating environment, we believe the share price has run its course and these fundamentals are fully reflected at the current share price,” writes analyst Sheikh Abdullah. He maintains his “hold” and target price of M$7.04 (US$1.67). Hartalega shares were last seen down 2.46% at M$6.54.
 
Maybank Kim Eng is positive on women’s healthcare specialist Singapore O&G (SOG) in a detailed new report on the unrated company. “Based on consensus estimates, SOG trades at 24x/20x FY17E/FY18E P/E. This is at a slight discount of 8%/20% vs Singapore peers’ PE of 26x/25x. On the other hand, SOG offers a respectable 4.0% dividend yield for FY17E, which is the second-highest among Singapore’s peers, which generate 0.5%-5.0% dividend yield,” writes analyst John Cheong.
 
Retirement village operator Arvida is to acquire three villages in New Zealand – Mary Doyle Lifecare, Strathallan Lifecare and 50% of Village at the Park Lifecare – from Hurst Lifecare for approximately NZ$106 million (US$76.7 million).
 
Oceania Healthcare, New Zealand’s third largest retirement village operator, has acquired a site adjacent to its Eden facility in Mt Eden, Auckland. Financial terms have not been disclosed.
 
Golden Equator, a group of five independently managed companies based in Singapore, has launched the Korea-Singapore Healthcare Incubator together with Korean regulatory and clinical research provider C&R Healthcare Global. The incubator will help 10 to15 Korean companies expand into Singapore and southeast Asia over the next few months.
 
In people news, Australian medical software developer Medadvisor has appointed two regional advisors to accelerate its global expansion strategy. Jamal Butt and Keith Kiarsis will lead MedAdvisor’s market entry strategies into the UK and US, respectively.
 
In our must-read for the day, Albert Wong argues that biomedical technology should not be ignored and explains how the Hong Kong Science and Technology Parks Corporation can support it.

Posted on: 13/09/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.